
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is a promising biopharmaceutical company in the genetic medicine space with a focus on RNA editing technology. Their lead program, KRRO-121, is designed to address hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. The company has a strong pipeline of programs and is well-funded, with a positive outlook for their upcoming AATD development candidate nomination in 2Q26. Key highlights include high-potency RNA editing, strong pre-clinical and NHP data, and a clear regulatory path established for their target indications. With a differentiated approach, strong potential market opportunity, and a solid financial standing, Korro Bio has a clear value proposition for investors looking for potential blockbuster opportunities and a risk-mitigated setup ahead of regulatory and clinical updates.
Bears say
Korro Bio is relying on a single lead asset, KRRO-121, to generate a stable variant of the enzyme glutamine synthase (GS) in order to address all patients with urea cycle disorder (UCD) and hepatic encephalopathy (HE), showcasing a limited pipeline and potential long-term success of the company. Furthermore, Korro Bio's lead asset is still in Phase 1 development and previous trials of RAVICTI, a similar treatment for UCD, have shown limited efficacy in reducing ammonia levels and rely solely on safety/tolerability as primary endpoints, indicating a lack of confidence in the drug's potential success. Finally, the company's sole source of revenue will be from this single asset, further highlighting the risk and limited potential returns for investors.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares